ClinicalTrials.gg
CompletedNCT01122251Updated Feb 18, 2011

Efficacy and Safety of Lercanidipine and Valsartan in Patients With Essential Hypertension

A Phase 2 interventional study of Lercanidipine + Valsartan and Lercanidipine or Valsartan in Essential Hypertension, sponsored by LG Life Sciences. Completed at 2 sites in Korea, Republic of. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2011-02-18.

Sponsored by LG Life Sciences (part of LG Chem) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
441
Allocation
Randomized
Ages
20 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing valsartan in Essential Hypertension — 2 open to participants now, 2 under way, 1 of them phase 3. Valsartan · Essential Hypertension.

Planned enrollment
5th of 10
441 · median 392
Started
2009
with 1 other
Phase 2
Only one
of the 10
Registered
4th of 10
by date
Lead sponsor
1 of 10
LG Life Sciences

Among the 10 studies testing valsartan in Essential Hypertension, this one is the 5th largest by planned enrollment, is one of 2 that started in 2009, is the only one in phase 2, and was the 4th registered.

Essential Hypertension

480 studies on the registry are indexed under Essential Hypertension; 76 are open to participants now.

Browse Essential Hypertension studies →

Open to participants now

2 of the 10 studies testing valsartan in Essential Hypertension are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About valsartan

Valsartan: first FDA approval 1996 (DIOVAN), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 45 Essential Hypertension studies recruiting now, 17 (38%) set no upper age limit and 20 (44%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.

This study: 20 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing valsartan in Essential Hypertension, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and efficacy of fixed combination of lercanidipine (10 mg or 20 mg) and valsartan (80 mg or 160 mg), lercanidipine and valsartan alone in reducing blood pressure. The study will investigate the dose response relationship for the combinations and monotherapies.

03

Conditions studied

  • Essential Hypertension

Keywords

  • hypertension
  • lercanidipine
  • valsartan
04

Who can participate

Ages eligible
20 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged between 20 and 75
  • Essential hypertension at screening (-3 week)

Randomization Criteria:

  • Essential hypertension at baseline (90mmHg≤sitDBP≤109mmHg, except sitSBP≥180)

Exclusion criteria

Exclusion Criteria:

  • Mean sitDBP≥110mmHg or sitSBP≥180
  • Secondary hypertension or suspected secondary hypertension
  • Uncontrolled diabetes
  • Severe heart disease or severe cerebrovascular disease
  • hematological test results, renal disease (serum creatinine) or liver disease ( or AST)
  • History of malignant disease
  • disease
  • Women with a positive pregnancy test result, breast feeding or intention of pregnancy during the trial
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Double (Participant, Investigator)
Enrollment
441 participants (estimated)

Study arms

  • Experimental
    Lercanidpine + Valsartan

    L10/V80, L20/V80, L10/V160, L20/V160

    Drug: Lercanidipine + Valsartan

  • Active comparator
    Lercanidipine or Valsartan

    L10, L20, V80, V160

    Drug: Lercanidipine or Valsartan

  • Placebo comparator
    Placebo

    Placebo comparators of Lercanidipine and Valsartan

    Drug: Placebo

Interventions

  • DrugLercanidipine + Valsartan

    Drug pages: Lercanidipine · Valsartan

    L10/V80, L20/V80, L10/V160, L20/V160

  • DrugLercanidipine or Valsartan

    L10, L20, V80, V160

  • DrugPlacebo

    Placebo of Lercanidipine and Valsartan

06

What researchers measure

Primary outcomes

  1. sitDBP

    Average changes from baseline in sitDBP

    Time frame: Baseline, Week 8

Secondary outcomes

  1. sitDBP

    Response rates (proportion of patients sitDBP\<90mmHg or ≥10-mmHg reduction from baseline)

    Time frame: Week 4, 8

  2. sitDBP

    Average changes from baselin in sitDBP

    Time frame: Week 4

  3. sitSBP

    Average changes from baselini in sitSBP

    Time frame: Week 4, 8

07

Study locations

2 sites
  • 23 sites in Korea
    Seoul, Busan etc., Korea, Republic of
  • Seoul National University Hospital
    Seoul, Korea, Republic of
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2009, a primary completion of May 2010 and a completion of Jul 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 11, 2010
First posted
May 13, 2010
Start
Dec 2009
Primary completionActual
May 2010
CompletionActual
Jul 2010
Last update
Feb 18, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01122251
Lead sponsor
LG Life Sciences
First posted
May 13, 2010
Start date
Dec 2009
Primary completion
May 2010
Completion
Jul 2010
Last update
Feb 18, 2011

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lercanidipine · Valsartan

Start the discussion